Published in Respir Med on July 16, 2013
A Study to Assess the Long-term Safety of QVA149 (ENLIGHTEN) | NCT01120717
Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest (2015) 2.32
New combination bronchodilators for chronic obstructive pulmonary disease: current evidence and future perspectives. Br J Clin Pharmacol (2015) 1.10
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis (2013) 1.05
LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.02
Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstruct Pulmon Dis (2015) 0.84
Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis (2015) 0.82
Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review. Int J Chron Obstruct Pulmon Dis (2014) 0.81
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.81
COPD: maximization of bronchodilation. Multidiscip Respir Med (2014) 0.80
LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes. Int J Chron Obstruct Pulmon Dis (2015) 0.79
Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct Pulmon Dis (2016) 0.78
Clinical role of dual bronchodilation with an indacaterol-glycopyrronium combination in the management of COPD: its impact on patient-related outcomes and quality of life. Int J Chron Obstruct Pulmon Dis (2015) 0.77
Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study. Int J Chron Obstruct Pulmon Dis (2015) 0.76
Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study. Int J Chron Obstruct Pulmon Dis (2016) 0.76
Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Dual bronchodilation in COPD: lung function and patient-reported outcomes - a review. Int J Chron Obstruct Pulmon Dis (2016) 0.75
Pharmacologic rationale, efficacy and safety of the fixed-dose co-formulation of indacaterol and glycopyrronium. Multidiscip Respir Med (2014) 0.75
Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Combination of glycopyrronium and indacaterol inhibits carbachol-induced ERK5 signal in fibrotic processes. Respir Res (2017) 0.75
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med (2012) 3.51
Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J (2006) 3.27
Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics (2007) 2.81
Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol (2003) 2.43
Sex differences in the application of evidence-based therapies for the treatment of acute myocardial infarction: the American College of Cardiology's Guidelines Applied in Practice projects in Michigan. Arch Intern Med (2006) 2.21
Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax (2009) 2.10
Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med (2014) 2.00
Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J (2012) 1.98
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
A cohort study of traffic-related air pollution and mortality in Toronto, Ontario, Canada. Environ Health Perspect (2009) 1.77
Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids. Ann Intern Med (2006) 1.71
Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest (2005) 1.60
Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol (2005) 1.60
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. Breast Cancer Res Treat (2002) 1.60
Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest (2010) 1.49
Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest (2006) 1.47
Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ (2010) 1.43
What's nice about the new NICE guideline? Thorax (2010) 1.40
The Ontario Asthma Regional Variation Study: emergency department visit rates and the relation to hospitalization rates. Chest (2006) 1.38
Iatrogenic aortic dissection. Am J Cardiol (2002) 1.35
Management of rheumatoid arthritis: summary of NICE guidance. BMJ (2009) 1.26
Asthma control in Canada: no improvement since we last looked in 1999. Can Fam Physician (2007) 1.24
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med (2014) 1.21
Enhanced bronchial expression of extracellular matrix proteins in chronic obstructive pulmonary disease. Am J Clin Pathol (2006) 1.17
Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vascul Pharmacol (2005) 1.16
What do we know about asthma triggers? a review of the literature. J Asthma (2012) 1.06
Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study. Int J Chron Obstruct Pulmon Dis (2013) 1.05
Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the need for longitudinal observational studies in COPD. COPD (2012) 1.04
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis. J Cyst Fibros (2009) 1.00
Role of extracellular matrix and its regulators in human airway smooth muscle biology. Cell Biochem Biophys (2006) 0.97
Variations and gaps in management of acute asthma in Ontario emergency departments. Chest (2008) 0.97
The coming of age of asthma guidelines. Lancet (2008) 0.96
Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol (2004) 0.96
Assessment of a medication-based asthma index for population research. Am J Respir Crit Care Med (2002) 0.95
Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin (2013) 0.93
Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med (2014) 0.92
Anterior minimally invasive approaches for the cervical spine. Orthop Clin North Am (2007) 0.92
Diffuse panbronchiolitis in a Caucasian man in Canada. Can Respir J (2003) 0.89
Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells. Eur J Cancer (2006) 0.89
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Bronchodilator responsiveness and reported respiratory symptoms in an adult population. PLoS One (2013) 0.89
A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. Anesthesiology (2012) 0.88
Profile of eicosanoids in breath condensate in asthma and COPD. J Breath Res (2012) 0.87
NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Ther Adv Respir Dis (2011) 0.86
Effect of montelukast on exhaled nitric oxide and nonvolatile markers of inflammation in mild asthma. Chest (2003) 0.86
Women and asthma: lessons from a gender analysis of the asthma in Canada survey. J Asthma (2006) 0.85
A novel model-based approach for dose determination of glycopyrronium bromide in COPD. BMC Pulm Med (2012) 0.85
The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS One (2013) 0.84
Omalizumab for asthma: pharmacology and clinical profile. Expert Rev Respir Med (2009) 0.84
Hot tub lung mimicking classic acute and chronic hypersensitivity pneumonitis: two case reports. Can Respir J (2007) 0.84
Types, frequency and impact of asthma triggers on patients' lives: a quantitative study in five European countries. J Asthma (2013) 0.84
Anti-progestins suppress the growth of established tumors induced by 7,12-dimethylbenz(a)anthracene: comparison between RU486 and a new 21-substituted-19-nor-progestin. Oncol Rep (2007) 0.83
Emphysema in alpha1-antitrypsin deficiency: does replacement therapy affect outcome? Treat Respir Med (2005) 0.83
Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J (2012) 0.83
Influence of current or former smoking on asthma management and control. Can Respir J (2008) 0.83
Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease. CMAJ (2012) 0.82
Economic issues in the use of office spirometry for lung health assessment. Can Respir J (2003) 0.82
The effect of montelukast on exhaled nitric oxide of alveolar and bronchial origin in inhaled corticosteroid-treated asthma. Respir Med (2008) 0.82
The value of early diagnosis for effective management of chronic obstructive pulmonary disease. J Fam Pract (2007) 0.82
Dynamic airway evaluation with volume CT: initial experience. Can Assoc Radiol J (2010) 0.82
Rapid-cycle improvement in quality of care for patients hospitalized with acute myocardial infarction or heart failure: moving from a culture of missed opportunity to a system of accountability. J Cardiovasc Manag (2005) 0.81
Evaluation of a questionnaire to assess compliance with anti-asthma medications. J Asthma (2004) 0.81
Effect of nasal triamcinolone acetonide on lower airway inflammatory markers in patients with allergic rhinitis. J Allergy Clin Immunol (2003) 0.81
Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros (2011) 0.80
Parent-reported symptoms may not be adequate to define asthma control in children. Pediatr Pulmonol (2007) 0.80
The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol (2003) 0.79
Tiotropium and simplified detection of dynamic hyperinflation. Chest (2007) 0.79
Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. Cell Biochem Biophys (2007) 0.79
Infection with Mycoplasma pneumoniae is not related to asthma control, asthma severity, and location of airway obstruction. Int J Gen Med (2010) 0.79
Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in Ontario. Can Respir J (2011) 0.78
Pharmacokinetic comparability of Prolastin®-C to Prolastin® in alpha₁-antitrypsin deficiency: a randomized study. BMC Clin Pharmacol (2010) 0.78
Management of atrial fibrillation: the NICE guidelines. Int J Clin Pract (2007) 0.78
Hepatic activation and inactivation of clinically-relevant vitamin D analogs and prodrugs. Anticancer Res (2006) 0.77
Transforming growth factor-beta 1 induces angiogenesis in vitro via VEGF production in human airway smooth muscle cells. Indian J Biochem Biophys (2011) 0.77
Low-dose fluticasone propionate with and without salmeterol in steroid-naïve patients with mild, uncontrolled asthma. Respir Med (2009) 0.76
SMART isn't. J Allergy Clin Immunol (2010) 0.76
Atrial fibrillation: Rate control and digoxin. BMJ (2007) 0.75
A step forward in COPD management: reading between the lines. Chest (2012) 0.75
Predicting the need for supplemental oxygen during airline flight in patients with chronic pulmonary disease: a comparison of predictive equations and altitude simulation. Can Respir J (2009) 0.75
COPD and death: what exactly is the relationship? Thorax (2007) 0.75
COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION. Endocr Pract (2016) 0.75
Indacaterol-Glycopyrronium for COPD. N Engl J Med (2016) 0.75
Seretide: a pharmacoeconomic analysis. J Med Econ (2008) 0.75
Asthma controller delay and recurrence risk after an emergency department visit or hospitalization. Respir Med (2012) 0.75
Alpha-1 antitrypsin deficiency in Canada: regional disparities in diagnosis and management. COPD (2015) 0.75
Validation of HPTLC and HPLC methods for the quantitative determination of allyl disulfide in some polyherbal oils. J AOAC Int (2013) 0.75
Focusing on COPD. Prof Nurse (2003) 0.75
Nitric oxide donors augment interleukin-1β-induced vascular endothelial growth factor in airway smooth muscle cells. Cell Biochem Biophys (2013) 0.75
Safety and clinical relief over 1 year with triamcinolone acetonide hydrofluoroalkane-134a nasal aerosol in patients with perennial allergic rhinitis. Allergy Asthma Proc (2006) 0.75
Clinical association between renal insufficiency and positive troponin I in patients with acute coronary syndrome. Cardiology (2004) 0.75
Determination of psoralen and plumbagin from its polyherbal oil formulations by an HPTLC densitometric method. J AOAC Int (2009) 0.75